Patents by Inventor Ludo Van Den Bosch

Ludo Van Den Bosch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEK6 Inhibition to Treat ALS and FTD
    Publication number: 20220313697
    Abstract: The present invention relates to the field of neurological diseases, particularly to neurodegenerative diseases caused by dipeptide repeat toxicity. The invention provides genetic and chemical inhibitors of the protein kinase NEK6 to treat amyotrophic lateral sclerosis and frontotemporal dementia.
    Type: Application
    Filed: March 23, 2022
    Publication date: October 6, 2022
    Inventors: Ludo VAN DEN BOSCH, Wenting GUO, Catherine VERFAILLIE
  • PYRIMIDINE HYDROXY AMIDE COMPOUNDS FOR TREATING PERIPHERAL NEUROPATHY
    Publication number: 20160158231
    Abstract: The invention relates to HDAC inhibitors for the treatment of peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor.
    Type: Application
    Filed: December 4, 2015
    Publication date: June 9, 2016
    Inventors: Matthew Blaire Jarpe, Ludo Van Den Bosch, Veronick Benoy, Lawrence Van Helleputte
  • HDAC inhibitors to treat charcot-marie-tooth disease
    Patent number: 9238028
    Abstract: The disclosure relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, such as Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: January 19, 2016
    Assignees: VIB VZW, Life Sciences Research Partners VZW
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
    Publication number: 20160000766
    Abstract: The present application relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, most particularly, Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Application
    Filed: September 16, 2015
    Publication date: January 7, 2016
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
    Publication number: 20140329849
    Abstract: The disclosure relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, such as Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 6, 2014
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
    Publication number: 20130227717
    Abstract: The present application relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, most particularly, Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Application
    Filed: October 6, 2011
    Publication date: August 29, 2013
    Applicant: Life Sciences Research Partners VZW
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht